6 active not recruiting. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 6 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) AHB-137, Placebo, NA therapy - Chronic Hepatitis B | Phase 3 | Active not recruiting | Ausper Biopharma Co., Ltd. | 577 | 2025-08-12 | 2026-05-04 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B HTS 20mg, HTS 30mg, HTS 40mg - Chronic Hepatitis B | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 1444 | 2025-07-01 | 2025-10-02 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-11-03 |
| Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection Tenofovir DF, TDF Placebo - Chronic Hepatitis B | Phase 3 | Active not recruiting | Gilead Sciences | 90 | 2012-12-06 | 2026-01-30 |
Hepatitis B, Chronic (3) · Hepatitis (2) · Hepatitis D (2) · Hepatitis D, Chronic (2) · Digestive System Diseases (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Liver Diseases (1)
Chronic Disease (6) · Disease Attributes (6) · Hepatitis, Viral, Human (6) · Infections (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Virus Diseases (6) · Digestive System Diseases (5) · Liver Diseases (5) · Blood-Borne Infections (4) · Communicable Diseases (4) · Hepatitis (4) · DNA Virus Infections (3) · Hepadnaviridae Infections (3)
Saline Solution, Hypertonic (1) · Tenofovir (1) · bulevirtide (1) · sofosbuvir-velpatasvir drug combination (1)
Vir Biotechnology, Inc. (2) · Atea Pharmaceuticals, Inc. (1) · Ausper Biopharma Co., Ltd. (1) · Gilead Sciences (1) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1)
Romania (4) · Germany (3) · China (2) · France (2) · India (2) · Moldova (2) · Pakistan (2) · South Korea (2) · Spain (2) · Ukraine (2) · United Kingdom (2) · United States (2) · Austria (1) · Canada (1) · Egypt (1)